<DOC>
	<DOC>NCT01434914</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled trial with octenisept® or placebo in patients with chronic leg ulcers. The study will be conducted at a single center with a total of 70 patients. Patients will be randomized to either the octenisept® group or to the placebo group.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds</brief_title>
	<detailed_description>Randomized, double-blind, placebo-controlled trial with octenisept® or placebo in patients with chronic leg ulcers. The study will be conducted at a single center with a total of 70 patients. Patients will be randomized to either the octenisept® group or to the placebo group. Primary Objectives: Antimicrobial efficacy of octenisept® compared to placebo. Secondary Objectives: Subjective tolerance of octenisept®, evaluation of wound parameters.</detailed_description>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Octenidine</mesh_term>
	<criteria>Male and female patients of at least 18 years at the time of consent Patients with a venous leg ulcer (Ulcus cruris) Patients with a chronic leg ulcer Females of childbearing potential who are willing to comply with any applicable contraceptive requirements of the protocol Negative pregnancy test Satisfactory medical assessment Ability to provide written informed consent Signed declaration of consent Willingness to cooperate Pregnant or lactating women and women not using contraception Known history of alcohol or drug abuse Use of any antibiotic medication within the last 7 days prior to the first dose Patients with serious concomitant disease Patients with a coagulation disorder Known history of allergic reactions attributed to octenisept® or one of its compounds Participation in another clinical trial within the last 30 days before randomization Concomitant treatment with other preparations that interfere with the trial preparation or the disease Absence of declaration of consent Doubt about willingness to cooperate Nonfulfilment of the inclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Ulcus cruris</keyword>
	<keyword>chronic wounds</keyword>
	<keyword>octenisept®</keyword>
</DOC>